Prospective Randomized Trial of Emtricitabine versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus–Infected Patients

We conducted a randomized, open-label, 10-day study that compared the antiretroviral activity of emtricitabine (FTC) 25, 100, and 200 mg once daily and lamivudine (3TC) 150 mg 2 times/day in 82 human immunodeficiency virus (HIV)–infected patients with virus loads >5000 and

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2003-12, Vol.188 (11), p.1652-1658
Hauptverfasser:	Rousseau, Franck S., Wakeford, Charles, Mommeja-Marin, Herve, Sanne, Ian, Moxham, Cary, Harris, Jeanette, Hulett, Laura, Wang, Laurene H., Quinn, Joseph B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anti-HIV Agents - therapeutic use antiretroviral therapy Antiretrovirals Antivirals Biological and medical sciences Blood plasma Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - blood Deoxycytidine - therapeutic use Dosage Dose response relationship Dose-Response Relationship, Drug Emtricitabine Fundamental and applied biological sciences. Psychology HIV HIV 1 HIV Infections - drug therapy Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lamivudine - adverse effects Lamivudine - blood Lamivudine - therapeutic use Medical sciences Microbiology Middle Aged Prospective Studies RNA Statistical significance Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We conducted a randomized, open-label, 10-day study that compared the antiretroviral activity of emtricitabine (FTC) 25, 100, and 200 mg once daily and lamivudine (3TC) 150 mg 2 times/day in 82 human immunodeficiency virus (HIV)–infected patients with virus loads >5000 and
ISSN:	0022-1899 1537-6613
DOI:	10.1086/379667